Cilostazol may improve cognition better than clopidogrel in non-surgical adult patients with ischemic moyamoya disease: subanalysis of a prospective cohort

Objective: Adult patients with ischemic moyamoya disease (MMD) who receive treatment with antiplatelet drugs reportedly show improvements in neuropsychological test scores after around 2 years. The purpose of the present study subanalyzing the same patient cohort used in a previous study was to dete...

Full description

Saved in:
Bibliographic Details
Published in:Neurological research (New York) 2019-05, Vol.41 (5), p.480-487
Main Authors: Ando, Satoshi, Tsutsui, Shouta, Miyoshi, Kenya, Sato, Shinpei, Yanagihara, Wataru, Setta, Kengo, Chiba, Takayuki, Fujiwara, Shunrou, Kobayashi, Masakazu, Yoshida, Kenji, Kubo, Yoshitaka, Ogasawara, Kuniaki
Format: Article
Language:English
Subjects:
adult
antiplatelet drug
cognition
Moyamoya disease
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: Adult patients with ischemic moyamoya disease (MMD) who receive treatment with antiplatelet drugs reportedly show improvements in neuropsychological test scores after around 2 years. The purpose of the present study subanalyzing the same patient cohort used in a previous study was to determine which antiplatelet drug, clopidogrel or cilostazol, results in better improvement of cognitive function among non-surgical adult patients showing ischemic MMD without severe hemodynamic compromise. Methods: Sixty-six patients without cerebral misery perfusion on 15 O gas positron emission tomography were treated with pharmacotherapy alone. Patients ≥50 years old and
ISSN:0161-6412
1743-1328
DOI:10.1080/01616412.2019.1580455